Leerink analyst Roanna Ruiz upgraded ARS Pharmaceuticals to Outperform from Market Perform with a price target of $18, up from $6. The analyst now has stronger conviction in ARS’s ability to execute the remaining regulatory steps for neffy ahead of a potential approval in the second half of 2024. The firm also sees pent-up demand from physicians and patients, “eager to adopt” neffy. Leerink came away from a meeting with management with a a more positive outlook on the company’s “abundance of preparation” ahead of neffy’s launch.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SPRY:
- ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
- ARS Pharmaceuticals reports neffy meets primary endpoints in Phase 2 study
- ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
- ARS Pharmaceuticals upgraded to Outperform from Market Perform at William Blair
- ARS Pharmaceuticals announces results from repeat dosing study of neffy